Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/india-to-join-global-hiv-vaccine-effort-16591/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/india-to-join-global-hiv-vaccine-effort-16591/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/india-to-join-global-hiv-vaccine-effort-16591/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/india-to-join-global-hiv-vaccine-effort-16591/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-trace').style.display = (document.getElementById('cakeErr680199a692011-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680199a692011-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-code').style.display = (document.getElementById('cakeErr680199a692011-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-context').style.display = (document.getElementById('cakeErr680199a692011-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680199a692011-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680199a692011-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 16463,
		&#039;title&#039; =&gt; &#039;India to join global HIV vaccine effort&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;
&lt;br /&gt;
The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;
&lt;br /&gt;
The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;
&lt;br /&gt;
Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;
&lt;br /&gt;
IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;
&lt;br /&gt;
Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;
&lt;br /&gt;
As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;
&lt;br /&gt;
Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 15 August, 2012, http://www.telegraphindia.com/1120815/jsp/nation/story_15858471.jsp#.UCuVfKAXVwc&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-to-join-global-hiv-vaccine-effort-16591&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 16591,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 16463,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India to join global HIV vaccine effort&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;HIV AIDS,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;&lt;br /&gt;The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;&lt;br /&gt;The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;&lt;br /&gt;Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;&lt;br /&gt;IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;&lt;br /&gt;Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;&lt;br /&gt;As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;&lt;br /&gt;Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 16463,
	&#039;title&#039; =&gt; &#039;India to join global HIV vaccine effort&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;
&lt;br /&gt;
The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;
&lt;br /&gt;
The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;
&lt;br /&gt;
Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;
&lt;br /&gt;
IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;
&lt;br /&gt;
Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;
&lt;br /&gt;
As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;
&lt;br /&gt;
Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 15 August, 2012, http://www.telegraphindia.com/1120815/jsp/nation/story_15858471.jsp#.UCuVfKAXVwc&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-to-join-global-hiv-vaccine-effort-16591&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 16591,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 16463
$metaTitle = &#039;LATEST NEWS UPDATES | India to join global HIV vaccine effort&#039;
$metaKeywords = &#039;HIV AIDS,Health&#039;
$metaDesc = &#039;
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;&lt;br /&gt;The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;&lt;br /&gt;The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;&lt;br /&gt;Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;&lt;br /&gt;IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;&lt;br /&gt;Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;&lt;br /&gt;As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;&lt;br /&gt;Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-to-join-global-hiv-vaccine-effort-16591.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India to join global HIV vaccine effort | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India to join global HIV vaccine effort</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.<br /><br />The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.<br /><br />India&rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.<br /><br />The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.<br /><br />&ldquo;We plan to recruit two principal investigators and four scientists for the lab,&rdquo; Vrati said.<br /><br />Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.<br /><br />&ldquo;For every two people on treatment, we have five new infections,&rdquo; said IAVI executive director Margaret McGlynn.<br /><br />IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &ldquo;broadly neutralising antibodies&rdquo; that are expected to protect people from HIV infections.<br /><br />Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.<br /><br />India&rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&rsquo;s treatment, Cipla said in a statement.<br /><br />&ldquo;While we&rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&rdquo; said Cipla chairperson Y.K. Hamied.<br /><br />As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.<br /><br />Studies of this drug combination &mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-trace').style.display = (document.getElementById('cakeErr680199a692011-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680199a692011-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-code').style.display = (document.getElementById('cakeErr680199a692011-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-context').style.display = (document.getElementById('cakeErr680199a692011-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680199a692011-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680199a692011-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 16463,
		&#039;title&#039; =&gt; &#039;India to join global HIV vaccine effort&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;
&lt;br /&gt;
The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;
&lt;br /&gt;
The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;
&lt;br /&gt;
Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;
&lt;br /&gt;
IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;
&lt;br /&gt;
Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;
&lt;br /&gt;
As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;
&lt;br /&gt;
Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 15 August, 2012, http://www.telegraphindia.com/1120815/jsp/nation/story_15858471.jsp#.UCuVfKAXVwc&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-to-join-global-hiv-vaccine-effort-16591&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 16591,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 16463,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India to join global HIV vaccine effort&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;HIV AIDS,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;&lt;br /&gt;The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;&lt;br /&gt;The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;&lt;br /&gt;Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;&lt;br /&gt;IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;&lt;br /&gt;Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;&lt;br /&gt;As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;&lt;br /&gt;Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 16463,
	&#039;title&#039; =&gt; &#039;India to join global HIV vaccine effort&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;
&lt;br /&gt;
The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;
&lt;br /&gt;
The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;
&lt;br /&gt;
Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;
&lt;br /&gt;
IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;
&lt;br /&gt;
Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;
&lt;br /&gt;
As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;
&lt;br /&gt;
Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 15 August, 2012, http://www.telegraphindia.com/1120815/jsp/nation/story_15858471.jsp#.UCuVfKAXVwc&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-to-join-global-hiv-vaccine-effort-16591&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 16591,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 16463
$metaTitle = &#039;LATEST NEWS UPDATES | India to join global HIV vaccine effort&#039;
$metaKeywords = &#039;HIV AIDS,Health&#039;
$metaDesc = &#039;
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;&lt;br /&gt;The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;&lt;br /&gt;The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;&lt;br /&gt;Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;&lt;br /&gt;IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;&lt;br /&gt;Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;&lt;br /&gt;As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;&lt;br /&gt;Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-to-join-global-hiv-vaccine-effort-16591.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India to join global HIV vaccine effort | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India to join global HIV vaccine effort</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.<br /><br />The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.<br /><br />India&rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.<br /><br />The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.<br /><br />&ldquo;We plan to recruit two principal investigators and four scientists for the lab,&rdquo; Vrati said.<br /><br />Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.<br /><br />&ldquo;For every two people on treatment, we have five new infections,&rdquo; said IAVI executive director Margaret McGlynn.<br /><br />IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &ldquo;broadly neutralising antibodies&rdquo; that are expected to protect people from HIV infections.<br /><br />Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.<br /><br />India&rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&rsquo;s treatment, Cipla said in a statement.<br /><br />&ldquo;While we&rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&rdquo; said Cipla chairperson Y.K. Hamied.<br /><br />As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.<br /><br />Studies of this drug combination &mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-trace').style.display = (document.getElementById('cakeErr680199a692011-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr680199a692011-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-code').style.display = (document.getElementById('cakeErr680199a692011-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr680199a692011-context').style.display = (document.getElementById('cakeErr680199a692011-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr680199a692011-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr680199a692011-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 16463,
		&#039;title&#039; =&gt; &#039;India to join global HIV vaccine effort&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;
&lt;br /&gt;
The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;
&lt;br /&gt;
The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;
&lt;br /&gt;
Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;
&lt;br /&gt;
IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;
&lt;br /&gt;
Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;
&lt;br /&gt;
As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;
&lt;br /&gt;
Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 15 August, 2012, http://www.telegraphindia.com/1120815/jsp/nation/story_15858471.jsp#.UCuVfKAXVwc&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;india-to-join-global-hiv-vaccine-effort-16591&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 16591,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 16463,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | India to join global HIV vaccine effort&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;HIV AIDS,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;&lt;br /&gt;The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;&lt;br /&gt;The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;&lt;br /&gt;Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;&lt;br /&gt;IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;&lt;br /&gt;Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;&lt;br /&gt;As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;&lt;br /&gt;Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 16463,
	&#039;title&#039; =&gt; &#039;India to join global HIV vaccine effort&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;
&lt;br /&gt;
The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;
&lt;br /&gt;
The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;
&lt;br /&gt;
Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;
&lt;br /&gt;
IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;
&lt;br /&gt;
Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;
&lt;br /&gt;
India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;
&lt;br /&gt;
As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;
&lt;br /&gt;
Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 15 August, 2012, http://www.telegraphindia.com/1120815/jsp/nation/story_15858471.jsp#.UCuVfKAXVwc&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;india-to-join-global-hiv-vaccine-effort-16591&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 16591,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 16463
$metaTitle = &#039;LATEST NEWS UPDATES | India to join global HIV vaccine effort&#039;
$metaKeywords = &#039;HIV AIDS,Health&#039;
$metaDesc = &#039;
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.&lt;br /&gt;&lt;br /&gt;The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.&lt;br /&gt;&lt;br /&gt;The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We plan to recruit two principal investigators and four scientists for the lab,&amp;rdquo; Vrati said.&lt;br /&gt;&lt;br /&gt;Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;For every two people on treatment, we have five new infections,&amp;rdquo; said IAVI executive director Margaret McGlynn.&lt;br /&gt;&lt;br /&gt;IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &amp;ldquo;broadly neutralising antibodies&amp;rdquo; that are expected to protect people from HIV infections.&lt;br /&gt;&lt;br /&gt;Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.&lt;br /&gt;&lt;br /&gt;India&amp;rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&amp;rsquo;s treatment, Cipla said in a statement.&lt;br /&gt;&lt;br /&gt;&amp;ldquo;While we&amp;rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&amp;rdquo; said Cipla chairperson Y.K. Hamied.&lt;br /&gt;&lt;br /&gt;As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.&lt;br /&gt;&lt;br /&gt;Studies of this drug combination &amp;mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &amp;mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/india-to-join-global-hiv-vaccine-effort-16591.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | India to join global HIV vaccine effort | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>India to join global HIV vaccine effort</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br />A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.<br /><br />The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.<br /><br />India&rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.<br /><br />The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.<br /><br />&ldquo;We plan to recruit two principal investigators and four scientists for the lab,&rdquo; Vrati said.<br /><br />Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.<br /><br />&ldquo;For every two people on treatment, we have five new infections,&rdquo; said IAVI executive director Margaret McGlynn.<br /><br />IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &ldquo;broadly neutralising antibodies&rdquo; that are expected to protect people from HIV infections.<br /><br />Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.<br /><br />India&rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&rsquo;s treatment, Cipla said in a statement.<br /><br />&ldquo;While we&rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&rdquo; said Cipla chairperson Y.K. Hamied.<br /><br />As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.<br /><br />Studies of this drug combination &mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 16463,
		'title' => 'India to join global HIV vaccine effort',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph<br />
<br />
A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.<br />
<br />
The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.<br />
<br />
India&rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.<br />
<br />
The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.<br />
<br />
&ldquo;We plan to recruit two principal investigators and four scientists for the lab,&rdquo; Vrati said.<br />
<br />
Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.<br />
<br />
&ldquo;For every two people on treatment, we have five new infections,&rdquo; said IAVI executive director Margaret McGlynn.<br />
<br />
IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &ldquo;broadly neutralising antibodies&rdquo; that are expected to protect people from HIV infections.<br />
<br />
Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.<br />
<br />
India&rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&rsquo;s treatment, Cipla said in a statement.<br />
<br />
&ldquo;While we&rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&rdquo; said Cipla chairperson Y.K. Hamied.<br />
<br />
As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.<br />
<br />
Studies of this drug combination &mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.
</div>',
		'credit_writer' => 'The Telegraph, 15 August, 2012, http://www.telegraphindia.com/1120815/jsp/nation/story_15858471.jsp#.UCuVfKAXVwc',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'india-to-join-global-hiv-vaccine-effort-16591',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 16591,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 16463,
	'metaTitle' => 'LATEST NEWS UPDATES | India to join global HIV vaccine effort',
	'metaKeywords' => 'HIV AIDS,Health',
	'metaDesc' => '
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,...',
	'disp' => '<div align="justify">-The Telegraph<br /><br />A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.<br /><br />The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.<br /><br />India&rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.<br /><br />The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.<br /><br />&ldquo;We plan to recruit two principal investigators and four scientists for the lab,&rdquo; Vrati said.<br /><br />Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.<br /><br />&ldquo;For every two people on treatment, we have five new infections,&rdquo; said IAVI executive director Margaret McGlynn.<br /><br />IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &ldquo;broadly neutralising antibodies&rdquo; that are expected to protect people from HIV infections.<br /><br />Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.<br /><br />India&rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&rsquo;s treatment, Cipla said in a statement.<br /><br />&ldquo;While we&rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&rdquo; said Cipla chairperson Y.K. Hamied.<br /><br />As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.<br /><br />Studies of this drug combination &mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 16463,
	'title' => 'India to join global HIV vaccine effort',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph<br />
<br />
A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.<br />
<br />
The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.<br />
<br />
India&rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.<br />
<br />
The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.<br />
<br />
&ldquo;We plan to recruit two principal investigators and four scientists for the lab,&rdquo; Vrati said.<br />
<br />
Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.<br />
<br />
&ldquo;For every two people on treatment, we have five new infections,&rdquo; said IAVI executive director Margaret McGlynn.<br />
<br />
IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &ldquo;broadly neutralising antibodies&rdquo; that are expected to protect people from HIV infections.<br />
<br />
Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.<br />
<br />
India&rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&rsquo;s treatment, Cipla said in a statement.<br />
<br />
&ldquo;While we&rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&rdquo; said Cipla chairperson Y.K. Hamied.<br />
<br />
As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.<br />
<br />
Studies of this drug combination &mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.
</div>',
	'credit_writer' => 'The Telegraph, 15 August, 2012, http://www.telegraphindia.com/1120815/jsp/nation/story_15858471.jsp#.UCuVfKAXVwc',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'india-to-join-global-hiv-vaccine-effort-16591',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 16591,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 16463
$metaTitle = 'LATEST NEWS UPDATES | India to join global HIV vaccine effort'
$metaKeywords = 'HIV AIDS,Health'
$metaDesc = '
-The Telegraph

A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.

The Translational Health Sciences and Technology Institute,...'
$disp = '<div align="justify">-The Telegraph<br /><br />A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy.<br /><br />The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV.<br /><br />India&rsquo;s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection.<br /><br />The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director.<br /><br />&ldquo;We plan to recruit two principal investigators and four scientists for the lab,&rdquo; Vrati said.<br /><br />Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections.<br /><br />&ldquo;For every two people on treatment, we have five new infections,&rdquo; said IAVI executive director Margaret McGlynn.<br /><br />IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called &ldquo;broadly neutralising antibodies&rdquo; that are expected to protect people from HIV infections.<br /><br />Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation.<br /><br />India&rsquo;s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day&rsquo;s treatment, Cipla said in a statement.<br /><br />&ldquo;While we&rsquo;re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,&rdquo; said Cipla chairperson Y.K. Hamied.<br /><br />As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said.<br /><br />Studies of this drug combination &mdash; one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir &mdash; have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

India to join global HIV vaccine effort

-The Telegraph A global effort to create a vaccine against the human immunodeficiency virus (HIV) that has abandoned dozens of candidate vaccines because of unsatisfactory trials has persuaded India to join its new vaccine-design strategy. The Translational Health Sciences and Technology Institute, a government research centre in a Haryana suburb near Delhi, will set up a laboratory for basic research to seek out molecules that can generate antibodies to effectively neutralise HIV. India’s biotechnology department will provide Rs 20 crore for the laboratory, with an equal amount expected to come from the International AIDS Vaccine Initiative, a 16-year global programme aimed at delivering a vaccine to prevent HIV infection. The THSTI-IAVI laboratory first announced by biotechnology department officials last year is expected to become operational within the next six months, said Sudhanshu Vrati, THSTI director. “We plan to recruit two principal investigators and four scientists for the lab,” Vrati said. Although anti-viral drugs can halt the progress of HIV infection, scientists say an effective vaccine will be necessary to dramatically reduce new infections. “For every two people on treatment, we have five new infections,” said IAVI executive director Margaret McGlynn. IAVI chief scientific officer Wayne Koff said the effort at the THSTI would be part of a new strategy supported by the IAVI aimed at finding ways to generate a class of antibodies called “broadly neutralising antibodies” that are expected to protect people from HIV infections. Scientists estimate that over the past two decades, some 70 candidate vaccines have been abandoned after laboratory, animal or human trials proved unsatisfactory. Only four vaccines had moved into human efficacy studies, but no candidate is ready yet for commercialisation. India’s drug company Cipla today said it has launched a four-drug kit to treat HIV infections priced at Rs 158 per kit. The kit has two tablets packaged in one strip, representing a single day’s treatment, Cipla said in a statement. “While we’re committed to making drugs affordable and accessible, we also endeavour to offer HIV-infected patients drugs that are potent, effective, patient-friendly and easy to take,” said Cipla chairperson Y.K. Hamied. As the tablets are in a single strip, a patient does not have to remember which tablet he has taken, and will not mistakenly take two of the same tablet on the same day, Hamied said. Studies of this drug combination — one tablet combines tenofovir with emtricitabine and the second combines atazanavir with ritonavir — have shown that it is effective and well tolerated by over 80 per cent of patients, Cipla added.